Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma

被引：26

作者：

Arcaini, L ^{[1
]}

Orlandi, E ^{[1
]}

Scotti, M ^{[1
]}

Brusamolino, E ^{[1
]}

Passamonti, F ^{[1
]}

Burcheri, S ^{[1
]}

Colombo, N ^{[1
]}

Vanelli, L ^{[1
]}

Sbalzarini, G ^{[1
]}

Lazzarino, M ^{[1
]}

机构：

[1] Univ Pavia, Policlin San Matteo, Div Hematol, IRCCS, I-27100 Pavia, Italy

来源：

CLINICAL LYMPHOMA | 2004年 / 4卷 / 04期

关键词：

D O I：

10.3816/CLM.2004.n.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Optimal treatment for splenic marginal zone lymphoma (MZL) is not clearly established. Splenectomy has been proposed as the treatment of choice in patients with cytopenias and/or symptoms caused by an enlarged spleen. Splenic MZL, which expresses the CD20 antigen on tumor cell surfaces, is a disease entity candidate to treatment with anti-CD20 monoclonal antibodies. We employed an immunochemotherapy regimen with rituximab/cyclophosphamide/vincristine in 3 patients with splenic MZL who had only a partial response following CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) or CHOP-like therapy. The immunochemotherapy regimen was well tolerated and all patients exhibited complete remission. To our knowledge, this is the first report of splenic MZL showing response to a combination of rituximab with chemotherapy.

引用

页码：250 / 252

页数：3